Celularity, a biotechnology company specializing in the development of tissue regeneration solutions thanks to the allogeneic transplantation of stem cells, stated it received $250 million in funding. The company founded in September 2017 by Bob Hariri, also its CEO, and Peter Diamandis, received funding from pharmaceutical companies such as Celgene and Sorrento Therapeutics, from the biotechnology sector such as United Therapeutics Corporation and by Human Longevity Inc., another research company in the field of longevity with the same two founders.